Fennec Pharmaceuticals (FENC) Return on Capital Employed (2011 - 2025)
Fennec Pharmaceuticals posted quarterly Return on Capital Employed of 3.07% for Q4 2025, down 877.0% year-on-year from 0.4% in Q4 2024, and up 75.48% on a QoQ basis from 12.52% in Q3 2025.
Fennec Pharmaceuticals (FENC) has 15 years of Return on Capital Employed data on file, last reported at 3.07% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed fell 877.0% year-over-year to 3.07%; the trailing twelve-month figure through Dec 2025 stood at 3.07% (down 877.0% YoY), and the FY2025 full-year result was 3.21%, down 1207.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 3.07%, up from 12.52% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 16.34% in Q1 2024 and bottomed at 142.25% in Q2 2023.
- The 5-year median for Return on Capital Employed is 68.76% (2021), against an average of 58.4%.
- The widest annual swing landed in 2022, when Return on Capital Employed tumbled 5171 bps; it then soared 15229 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 76.34% in 2021, then declined by 23 bps to 93.85% in 2022, then gained by 14 bps to 80.48% in 2023, then surged by 107 bps to 5.7% in 2024, then plunged by 154 bps to 3.07% in 2025.
- The last three Return on Capital Employed figures came in at 3.07% (Q4 2025), 12.52% (Q3 2025), and 25.99% (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Fennec Pharmaceuticals | 281.48 Mn | 244.70 Mn | 7.67 Mn | -3.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.07% |
| Sep 30, 2025 | -12.52% |
| Jun 30, 2025 | -25.99% |
| Mar 31, 2025 | -32.12% |
| Dec 31, 2024 | 5.70% |
| Sep 30, 2024 | 3.14% |
| Jun 30, 2024 | 10.04% |
| Mar 31, 2024 | 16.34% |
| Dec 31, 2023 | -80.48% |
| Sep 30, 2023 | -108.19% |
| Jun 30, 2023 | -142.25% |
| Mar 31, 2023 | -119.42% |
| Dec 31, 2022 | -93.85% |
| Sep 30, 2022 | -102.97% |
| Jun 30, 2022 | -118.25% |
| Mar 31, 2022 | -84.99% |
| Dec 31, 2021 | -76.34% |
| Sep 30, 2021 | -65.32% |
| Jun 30, 2021 | -66.54% |
| Mar 31, 2021 | -70.98% |
| Dec 31, 2020 | -58.84% |
| Sep 30, 2020 | -53.81% |
| Jun 30, 2020 | -65.56% |
| Mar 31, 2020 | -136.85% |
| Dec 31, 2019 | -101.99% |
| Sep 30, 2019 | -78.06% |
| Jun 30, 2019 | -75.16% |
| Mar 31, 2019 | -55.51% |
| Dec 31, 2018 | -46.67% |
| Sep 30, 2018 | -42.24% |
| Jun 30, 2018 | -36.02% |
| Mar 31, 2018 | -30.14% |
| Dec 31, 2017 | -39.72% |
| Sep 30, 2017 | -61.72% |
| Jun 30, 2017 | -63.94% |
| Mar 31, 2017 | -99.53% |
| Dec 31, 2016 | -74.11% |
| Sep 30, 2016 | -50.78% |
| Jun 30, 2016 | -85.59% |
| Mar 31, 2016 | -412.65% |
| Dec 31, 2015 | -247.54% |
| Sep 30, 2015 | -173.24% |
| Jun 30, 2015 | -209.47% |
| Mar 31, 2015 | -269.11% |
| Dec 31, 2014 | 1,216.49% |
| Sep 30, 2014 | 82.30% |
| Jun 30, 2014 | 43.12% |
| Mar 31, 2014 | 46.47% |
| Dec 31, 2013 | 96.02% |
| Mar 31, 2013 | 39.99% |
| Dec 31, 2012 | 77.42% |
| Dec 31, 2011 | -1,011.47% |